Research Analysts Offer Predictions for Merck & Co.’s Q1 2018 Earnings (MRK)

Merck & Co. (NYSE:MRK) – Research analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for Merck & Co. in a research note issued to investors on Friday, April 13th. Jefferies Group analyst I. Hilliker expects that the company will post earnings per share of $0.99 for the quarter. Jefferies Group has a “Hold” rating and a $56.00 price objective on the stock. Jefferies Group also issued estimates for Merck & Co.’s FY2018 earnings at $4.14 EPS, FY2020 earnings at $4.51 EPS and FY2022 earnings at $5.01 EPS.

How to Become a New Pot Stock Millionaire

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Friday, February 2nd. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Merck & Co. had a return on equity of 28.61% and a net margin of 6.40%. The company had revenue of $10.43 billion during the quarter, compared to the consensus estimate of $10.48 billion. During the same quarter in the prior year, the firm earned $0.89 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year.

MRK has been the subject of a number of other research reports. ValuEngine downgraded Merck & Co. from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. DZ Bank upgraded Merck & Co. from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. Morgan Stanley increased their target price on Merck & Co. from $60.00 to $63.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Credit Suisse Group reduced their target price on Merck & Co. from $67.00 to $66.00 and set an “outperform” rating for the company in a report on Monday, February 5th. Finally, BMO Capital Markets restated a “buy” rating and issued a $65.00 target price on shares of Merck & Co. in a report on Monday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the stock. Merck & Co. presently has a consensus rating of “Buy” and an average price target of $66.53.

Shares of NYSE:MRK opened at $58.65 on Monday. Merck & Co. has a one year low of $52.83 and a one year high of $66.41. The firm has a market cap of $154,141.17, a PE ratio of 14.74, a P/E/G ratio of 2.41 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.33 and a quick ratio of 1.06.

Several hedge funds and other institutional investors have recently bought and sold shares of MRK. Santori & Peters Inc. acquired a new position in Merck & Co. during the fourth quarter worth $110,000. NewSquare Capital LLC increased its position in Merck & Co. by 728.3% during the third quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock worth $115,000 after buying an additional 13,014 shares during the last quarter. Stevens First Principles Investment Advisors increased its position in Merck & Co. by 79.3% during the fourth quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock worth $117,000 after buying an additional 920 shares during the last quarter. Avestar Capital LLC acquired a new position in Merck & Co. during the fourth quarter worth $130,000. Finally, Balentine LLC increased its position in Merck & Co. by 1.0% during the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after buying an additional 20 shares during the last quarter. 74.60% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Wendell P. Weeks sold 5,000 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $53.57, for a total value of $267,850.00. Following the transaction, the director now directly owns 5,100 shares of the company’s stock, valued at $273,207. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.32% of the company’s stock.

The business also recently declared a quarterly dividend, which was paid on Friday, April 6th. Stockholders of record on Thursday, March 15th were paid a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date was Wednesday, March 14th. Merck & Co.’s dividend payout ratio (DPR) is presently 48.24%.

COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/17/research-analysts-offer-predictions-for-merck-co-s-q1-2018-earnings-mrk.html.

About Merck & Co.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Earnings History and Estimates for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply